GlassScriptPhysician profile
Radhika Annam
NPI 1194107102
$957.45
in general payments reported to CMS, 2019-2025
16 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $16.18 · 2021: $137 · 2022: $235 · 2023: $125 · 2024: $198 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $173.40 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $137.56 | 2022-2024 | Repatha |
| Shire North American Group INC | $112.14 | 2019 | |
| Insulet Corporation | $84.85 | 2021-2023 | Omnipod |
| Dexcom, INC. | $83.29 | 2021-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $71.20 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $54.26 | 2021-2024 | |
| Tandem Diabetes Care, INC. | $47.85 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $42.56 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $31.92 | 2021-2023 | Freestyle Libre 3 |
| Medtronic, INC. | $28.43 | 2022-2024 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $24.49 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $20.16 | 2024 | |
| Medtronic Minimed, INC. | $16.18 | 2020 | |
| Corcept Therapeutics | $14.90 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $14.26 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radhika Annam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.